Clinical outcomes and survival surrogacy studies of prostate‐specific antigen declines following enzalutamide in men with metastatic castration‐resistant prostate cancer previously treated with docetaxel

BACKGROUND: In the AFFIRM trial, enzalutamide significantly increased overall survival (OS) for men with metastatic castration‐resistant prostate cancer (mCRPC) after chemotherapy versus placebo and significantly decreased prostate‐specific antigen (PSA) levels. The goal of this post hoc analysis wa...

Descripción completa

Detalles Bibliográficos
Autores principales: Armstrong, Andrew J., Saad, Fred, Phung, De, Dmuchowski, Carl, Shore, Neal D., Fizazi, Karim, Hirmand, Mohammad, Forer, David, Scher, Howard I., Bono, Johann De
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5484320/
https://www.ncbi.nlm.nih.gov/pubmed/28171710
http://dx.doi.org/10.1002/cncr.30587

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5484320/
https://www.ncbi.nlm.nih.gov/pubmed/28171710
http://dx.doi.org/10.1002/cncr.30587

Ejemplares similares